OxfordBioTherapeutics
Location: United Kingdom, England, Oxford
Total raised: $20M
Founded date: 2004
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.01.2017 | - | $10M | - |
| 30.07.2015 | - | $10M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 07.03.2024 | Oxford BioTherapeutics Announces Launch of Enhanced Discover... | - | globenewsw... |
| 03.10.2022 | Oxford BioTherapeutics enters into Commercial License Agreem... | • OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) ant... | alsaventur... |
| 07.04.2022 | AACR 2022: Oxford BioTherapeutics to Present Potential Novel... | AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combinatio... | alsaventur... |
| 01.04.2021 | San Jose BioCube Embarks on Next Phase of Plan to Attract th... | BioCube's new facility blends highly advanced biotech workplace environments with a modern lab desig... | prweb.com/... |
| 19.01.2021 | Oxford BioTherapeutics Designates Second Bispecific Antibody... | OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 (GLOBE NEWSWIRE) -- W... | alsaventur... |
| 06.01.2021 | Kite and Oxford BioTherapeutics Establish Cell Therapy Resea... | Santa Monica, Calif.; Oxford, UK; and San Jose, Calif., January 6 2021 - Kite, a Gilead Company (Nas... | alsaventur... |
| 14.10.2020 | Boehringer Ingelheim and Oxford BioTherapeutics Expand Colla... | The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s uniq... | alsaventur... |
| 31.03.2020 | Oxford BioTherapeutics Announces Second Oncology Drug Candid... | The Boehringer Ingelheim drug candidates are two of several assets approaching or in clinical develo... | alsaventur... |
| 09.01.2020 | Oxford BioTherapeutics Initiates Dose-Escalation Portion of ... | Oxford, UK and San Jose, Calif., January 9 2020 – Oxford BioTherapeutics Ltd. (“OBT”), a clinical st... | alsaventur... |
| 12.12.2018 | Art Krieg moves from CEO post to CSO at Checkmate; Indiv... | Art Krieg → Art Krieg is turning in his spot in the CEO’s suite in exchange for the CSO’s job at C... | endpts.com... |
Show more